- Home
- MDCX vs RLAY Comparison
MDCX vs RLAY Comparison
Compare MDCX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | RLAY |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MDCX | RLAY |
|---|---|---|
| Price | $1.63 | $8.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $23.50 | $16.00 |
| AVG Volume (30 Days) | 374.2K | ★ 2.3M |
| Earning Date | 02-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.45 | $1.78 |
| 52 Week High | $8.94 | $9.04 |
Technical Indicators
Market Signals| Indicator | MDCX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 53.65 |
| Support Level | $1.45 | $8.25 |
| Resistance Level | $1.65 | $8.58 |
| Average True Range (ATR) | 0.15 | 0.46 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 27.51 | 33.46 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).